Tags : Nexium

AstraZeneca Divests Rights of its Nexium and Vimovo Product to

Shots: AZ will receive an upfront $700M & $115M plus milestone payments up to $90M & $17M for Nexium (esomeprazole) and Vimovo (naproxen/esomeprazole) respectively. Grunenthal to get commercialization rights for Nexium in EU & WW rights for Vimovo (except in the US & Japan) AZ will continue to manufacture and supply Nexium under the long-term […]Read More